Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

Article Oncology

Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)

Francesca Romana Mauro et al.

Summary: Pneumococcal vaccination response was analyzed in 112 CLL patients, with factors like age, IgG levels, prior treatment, and disease progression being associated with lower immune response rates. Age ≥ 60 years, IgG levels < 400 mg/L, prior treatment, and signs of disease progression were linked to a decreased response rate.

LEUKEMIA (2021)

添加到收藏夹

Article Hematology

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Christopher Pleyer et al.

Summary: Treatment with BTK inhibitors resulted in a lower immune response rate to the HepB-CpG vaccine, but did not significantly affect the response rate to the RZV vaccine in CLL patients.

BLOOD (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Ilies Benotmane et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Letter Hematology